Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05174416
Other study ID # LB2001-301
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date January 4, 2022
Est. completion date August 2024

Study information

Verified date March 2024
Source LianBio LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Mavacamtenis a novel, small molecule, selective allosteric inhibitor of cardiac-specific myosin, for the treatment of patients with symptomatic oHCM. This study will assess the efficacy and safety of mavacamten in Chinese adults with symptomatic oHCM.


Description:

This is a randomized, double-blinded, placebo-controlled clinical study witha long-term extension to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic oHCM. Approximately 81eligible participants will be enrolled and randomized in a 2:1 ratio (mavacamten:placebo). Participants will receive mavacamten or matching placebofor 30 weeks indouble-blinded manner. After 30-week double-blinded placebo-controlled treatment, eligible participants will receive mavacamten for additional 48 weeks (placebogroup: switch from placebo to mavacamten, mavacamten group: maintain on mavacamten).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 81
Est. completion date August 2024
Est. primary completion date March 6, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Is at least 18 years old at screening. - Body weight is greater than 45 kg at screening. - Has adequate acoustic windows to enable accurate TTEs - Diagnosed with oHCM - Has documented LVEF = 55% at rest. - Has a valid measurement of Valsalva LVOT peak gradient at screening - Has NYHA Class II or III symptoms at screening - Female participants must not be pregnant or lactating - Able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent according to national, local, and institutional guidelines before the first study specific procedure. Exclusion Criteria: - Participated in a clinical trial in which the participant received any investigational drug (or is currently using an investigational device) within 30 days prior to screening, or at least 5 times the respective elimination half-life (if known), whichever is longer. - Causing cardiac hypertrophy in other reasons - Previously participated in a clinical study with mavacamten. - Hypersensitivity to any of the components of the mavacamten formulation. - Current treatment (within 14 days prior to screening) or planned treatment during the double-blinded treatment with a combination of beta-blockers and verapamil or a combination of beta-blockers and diltiazem. - Has been successfully treated with invasive septal reduction - Has documented obstructive coronary artery disease - Has known moderate or severe (as per investigator's judgment) aortic valve stenosis, constrictive pericarditis, or clinically significant congenital heart disease at screening. - Has any acute or serious comorbid condition that, in the judgment of the investigator, could lead to premature termination of study participation or interfere with the measurement or interpretation of the efficacy and safety assessments in the study. - History of malignant disease within 10 years of screening - Has safety laboratory parameters outside normal limits at screening as assessed by the local laboratory - Has a positive serologic test at screening for infection with human immunodeficiency virus, hepatitis C virus, or hepatitis B virus surface antigen. - Known uncured COVID-19 (coronavirus disease 2019) infection or with severe complication before screening. - Has a history or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion. - Prior treatment with cardio toxic agents. - Unable to comply with the study requirements, including the number of required visits to the clinical site. - Is a first degree relative of personnel directly affiliated with the study at the clinical study site, any study vendor, or the study sponsor. - Identified as alcohol addicts.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Mavacamten
Mavacamten Capsules
Placebo
Matching PBO capsules during placebo controlled period,and mavacamten capsules during long term extension period

Locations

Country Name City State
China Peking Union Medical College Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
LianBio LLC

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline to Week 30 in Valsalva left ventricular outflow tract (LVOT) peak gradient To compare the effect of a 30-week course of mavacamten with placebo on Valsalva LVOT peak gradient as determined by Doppler echocardiography 30 weeks
Secondary Change from baseline to Week 30 in resting LVOT peak gradient To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction. 30 weeks
Secondary Proportion of participants achieving a Valsalva LVOT peak gradient < 30 mmHg at Week 30 To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction. 30 weeks
Secondary Proportion of participants achieving a Valsalva LVOT peak gradient < 50 mmHg at Week 30. To compare the effect of a 30-week course of mavacamten with placebo on LVOT obstruction. 30 weeks
Secondary Proportion of participants with at least 1 class improvement in New York Heart Association (NYHA) functional classification from baseline to Week 30 To compare the effect of a 30-week course of mavacamten with placebo on clinical symptoms 30 weeks
Secondary Change from baseline to Week 30 in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) To compare the effect of a 30-week course of mavacamten with placebo on Participant-Reported health status individually 30 weeks
Secondary Change from baseline to Week 30 in N-terminal pro-B-type natriuretic peptide (NT-proBNP) To compare the effect of a 30-week course of mavacamten on cardiac biomarkers 30 weeks
Secondary Change from baseline to Week 30 in cardiac troponin To compare the effect of a 30-week course of mavacamten on cardiac biomarkers 30 weeks
Secondary Change from baseline to Week 30 in left ventricular (LV) mass index To compare the effect of a 30-week course of mavacamten with placebo on LV mass evaluated by cardiac magnetic resonance (CMR) imaging. 30 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06023186 - Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
Completed NCT05726799 - Use of Cryoenergy to Faciltate Myectomy in Hypertrophic Obstructive Cardiomyopathy: Comparison With the Classical Approach
Active, not recruiting NCT03723655 - A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM Phase 2/Phase 3
Completed NCT04603521 - Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
Active, not recruiting NCT06211595 - Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy N/A
Recruiting NCT06116968 - An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM Phase 3
Completed NCT03470545 - Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Phase 3
Recruiting NCT05879523 - A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy Phase 1
Not yet recruiting NCT06146660 - A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Recruiting NCT05771987 - Permanent Pacing for Drug-refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. N/A
Recruiting NCT06224621 - Percutaneous Endocardial Septal Radiofrequency Ablation in Obstructive Hypertrophic Cardiomyopathy N/A
Completed NCT01631006 - Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy N/A
Not yet recruiting NCT06368037 - Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy N/A
Recruiting NCT05489705 - A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive HCM)
Completed NCT06354556 - Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects Phase 1
Completed NCT04783766 - Safety, Tolerability and Pharmacokinetics Study of CK-3773274 Phase 1